How Clemmer was paid
$6.1M in total for fiscal Year 2026, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|
| James C. ClemmerPresident, CEO | $828,171 | $3,689,866 | $1,502,491 | $39,617 | $6,060,145 |
| Stephen A. TrowbridgeEVP, CFO | $471,305 | $1,556,376 | $598,538 | $35,751 | $2,661,970 |
| Lawrence T. WeissSVP, Chief Legal Officer & Corporate Secretary | $439,427 | $552,801 | $478,332 | $23,769 | $1,494,329 |
| Laura PiccininiSVP & GM, Cardiovascular and International | $470,563 | $580,047 | $500,422 | $57,655 | $1,608,687 |
| Warren NighanSVP & GM, Global Supply Chain, Quality and Regulatory Affairs | $416,304 | $525,054 | $454,313 | $35,811 | $1,431,482 |
What changed and why
- $6.1M$6,060,145 was CEO total compensation in fiscal 2026, up from $5,494,285 in fiscal 2025.
- $3.7M$3,689,866 of CEO compensation came from stock awards, with no option awards reported.
- $1.5M$1,502,491 was the CEO’s fiscal 2026 non-equity incentive compensation.
- $136K45:1 was the CEO-to-median-employee pay ratio, based on median employee compensation of $135,741.
- $30,000$30,000 per month was the consulting fee agreed for retiring CEO James C. Clemmer after his November 2, 2026 retirement.
- Relative TSR, EBITDA, EPS and revenue were identified as key fiscal 2026 performance measures.
Other Angiodynamics proxy statements
- 2025 proxy statement
James C. Clemmer paid $5.5M (+10% on the year), pay ratio 44:1.
Filed Sep 25, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.